Heron Therapeutics Inc vs Invesco NASDAQ 100 ETF — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $61.47M), while Invesco NASDAQ 100 ETF trades at $298.07. The key difference: Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | QQQM | |
|---|---|---|
Market Cap | $61.47M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.49 | $307.23 |
52-Week Low | $0.32 | $229.87 |
Enterprise Value | $168.21M | — |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.3409, up 3.24% today, but faces bearish technical signals with 18 sell indicators versus 6 buys. The company reported Q2 2026 revenue of $37.7 million but missed earnings expectations with a $0.03 per share loss. Despite strong analyst support (94.7% buy ratings), fundamental challenges persist with negative net income margins and elevated EV/EBITDA of 34.03.
Investment outlook remains cautious due to consistent earnings misses and negative cash flow from operations. The primary opportunity lies in analyst optimism and potential product growth, while risks include ongoing profitability challenges and competitive pressures in the biotechnology sector.
QQQM trades at $297.98, up 0.4% with a bullish technical outlook supported by moving averages. The ETF tracks the Nasdaq-100 index with lower fees than its QQQ counterpart, making it attractive for long-term investors. Recent news highlights its popularity among growth-focused investors and retirees seeking exposure to technology and innovation stocks.
The ETF's performance remains tied to the 'Magnificent Seven' tech stocks, with historical annual returns around 14%. While technical indicators show bullish momentum, the elevated RSI suggests potential near-term consolidation. Key risks include concentration in tech sector and market volatility affecting growth stocks.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →